NYSE:DHRLife Sciences
Danaher’s US$9.9b Masimo Deal Refocuses Growth On Diagnostics Valuation
Danaher (NYSE:DHR) has agreed to acquire Masimo Corporation in a cash and stock deal valued at $9.9b.
Masimo, a specialty diagnostics leader, will operate as a standalone business within Danaher’s Diagnostics segment.
The transaction is intended to expand Danaher’s presence in healthcare technology and diagnostic solutions.
Danaher, trading at around $209.94 per share, is pursuing one of its largest deals as it looks to deepen its role in diagnostics. The stock is up 1.7% over the past year...